New drug duo takes on Hard-to-Treat prostate cancer
NCT ID NCT06190899
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs—gedatolisib and darolutamide—together in men with metastatic castration-resistant prostate cancer (mCRPC), a type that has spread and no longer responds to standard hormone therapy. The first part finds the safest dose, and the second checks if the combo slows cancer growth. About 54 men will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gedatolisib and darolutamide
What this could lead to
If this works, it could offer a new combination treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is an early-phase trial with only 54 participants, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Barbara Ann Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
-
Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospita
NOT_YET_RECRUITINGCambridge, CB20QQ, United Kingdom
-
Centre Antoine Lacassagne
NOT_YET_RECRUITINGNice, 06100, France
-
Centre Jean Perrin
NOT_YET_RECRUITINGClermont-Ferrand, 63011, France
-
Hospital 12 de Octubre
RECRUITINGMadrid, 28045, Spain
-
Hospital Clinic Barcelona
RECRUITINGBarcelona, 08036, Spain
-
Hospital General Universitario Gregorio Maranon
NOT_YET_RECRUITINGMadrid, 28007, Spain
-
Institut Catala d'Oncologia
RECRUITINGBarcelona, 08908, Spain
-
Institut Gustave Roussy
NOT_YET_RECRUITINGVillejuif, 94805, France
-
Institut Paoli-Calmettes
NOT_YET_RECRUITINGMarseille, 13009, France
-
Instituto Valenciano de Oncología
NOT_YET_RECRUITINGValencia, 46009, Spain
-
Royal Marsden NHS Foundation Trust
RECRUITINGSutton, SM25PT, United Kingdom
-
University Hospital Southampton NHS Foundation Trust - Southampton General Hospital
NOT_YET_RECRUITINGSouthampton, SO16 6YD, United Kingdom